Johnson & Johnson Price to Free Cash Flow Ratio 2010-2024 | JNJ

Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Johnson & Johnson Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-04-23 149.56 20.58
2023-12-31 155.56 $7.27 21.41
2023-09-30 153.36 $6.28 24.42
2023-06-30 161.82 $5.63 28.77
2023-03-31 150.39 $6.23 24.13
2022-12-31 170.20 $6.65 25.58
2022-09-30 156.39 $6.80 23.01
2022-06-30 168.80 $9.31 18.13
2022-03-31 167.48 $9.01 18.58
2021-12-31 160.62 $10.36 15.51
2021-09-30 150.63 $11.59 13.00
2021-03-31 151.44 $8.14 18.60
2020-12-31 144.12 $7.67 18.78
2020-09-30 135.38 $6.91 19.59
2020-06-30 127.04 $6.65 19.11
2020-03-31 117.63 $8.50 13.83
2019-12-31 130.01 $8.64 15.05
2019-09-30 114.52 $11.46 9.99
2019-06-30 123.28 $6.74 18.29
2019-03-31 122.89 $5.81 21.14
2018-12-31 112.71 $6.88 16.39
2021-06-30 152.74 $3.20 47.72
2018-09-30 119.91 $7.48 16.04
2018-06-30 104.60 $7.70 13.58
2018-03-31 109.66 $7.36 14.89
2017-12-31 118.81 $7.14 16.63
2017-09-30 109.88 $7.11 15.45
2017-06-30 111.10 $6.62 16.78
2017-03-31 103.92 $6.33 16.42
2016-12-31 95.50 $6.03 15.85
2016-09-30 97.25 $5.86 16.58
2016-06-30 99.20 $6.19 16.02
2016-03-31 87.86 $6.66 13.20
2015-12-31 82.81 $6.96 11.90
2015-09-30 74.71 $6.13 12.19
2015-06-30 77.39 $6.80 11.38
2015-03-31 79.31 $6.56 12.09
2014-12-31 81.86 $6.85 11.95
2014-09-30 82.91 $6.76 12.27
2014-06-30 80.83 $5.83 13.88
2014-03-31 75.37 $5.49 13.72
2013-12-31 69.77 $4.96 14.06
2013-09-30 65.58 $4.94 13.29
2013-06-30 64.47 $4.71 13.68
2013-03-31 60.76 $4.64 13.09
2012-12-31 51.83 $4.97 10.43
2012-09-30 50.51 $5.02 10.06
2012-06-30 49.07 $5.05 9.71
2012-03-31 47.45 $4.83 9.83
2011-12-31 46.77 $4.59 10.18
2011-09-30 45.00 $4.62 9.73
2011-06-30 46.59 $4.71 9.89
2011-03-31 41.14 $4.72 8.72
2010-12-31 42.56 $5.21 8.17
2010-09-30 42.27 $5.76 7.34
2010-06-30 39.91 $5.69 7.02
2010-03-31 43.66 $5.50 7.93
2009-12-31 42.81 $5.15 8.31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $359.347B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $694.884B 115.72
Novo Nordisk (NVO) Denmark $562.108B 46.31
Merck (MRK) United States $321.543B 84.63
AbbVie (ABBV) United States $297.274B 15.11
AstraZeneca (AZN) United Kingdom $217.434B 19.27
Novartis AG (NVS) Switzerland $194.425B 13.97
Pfizer (PFE) United States $148.698B 14.35
Sanofi (SNY) $119.271B 10.74
Innoviva (INVA) United States $0.944B 6.67